Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study

Table 5 Hazard ratio (HRs) and 95 % confidence intervals (CIs) for fractures in the tamoxifen users compared with non-users using the time-dependent model stratified by comorbidity

Comorbidity	Tamoxifen user vs. non-user HR (95 % CI)	p-value	Interaction p
Hypertension			0.18
No	0.67 (0.53-0.85)	0.001
Yes	0.55 (0.46-0.66)	<0.0001
Hyperlipidemia			0.97
No	0.60 (0.50-0.72)	<0.0001
Yes	0.58 (0.45-0.74)	<0.0001
Diabetes			0.56
No	0.62 (0.52-0.74)	<0.0001
Yes	0.54 (0.41-0.71)	<0.0001
PAD			0.58
No	0.59 (0.50-0.68)	<0.0001
Yes	0.73 (0.37-1.46)	0.38
Stroke			0.32
No	0.59 (0.50-0.69)	<0.0001
Yes	0.68 (0.41-1.13)	0.14
Osteoporosis			0.33
No	0.61 (0.51-0.73)	<0.0001
Yes	0.54 (0.40-0.72)	<0.0001

PAD, peripheral artery disease
Manually adjusted for monthly income, comorbidity and aromatase inhibitor use before the end point